Payment overview · 2025
General Payments
$758.04
40 reported records · 16 companies
Healthcare provider profile · identity verified
Satish Ramesh Bagdure, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALLEN, TX · NPI 1316264971
Verified facts
What the public records show
CMS Open Payments records show Satish Ramesh Bagdure, M.D. received $758.04 in general payments during 2025 across 40 reported records.
Sumitomo Pharma America, Inc. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $154.09 | 20.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.64 | 14.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.86 | 12.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.12 | 8.8% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $57.41 | 7.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.78 | 7.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.36 | 6.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.58 | 4.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.54 | 3.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.24 | 2.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.95 | 2.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.92 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.77 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.35 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.21 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.22 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.04 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $154.09 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.64 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.86 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.12 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $57.41 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
212 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
120 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 185 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 555 | 123 |
| Losartan Potassium | Losartan Potassium | 475 | 133 |
| Gabapentin | Gabapentin | 384 | 125 |
| Potassium Chloride | Potassium Chloride | 378 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 103 |
| Mounjaro | Tirzepatide | 273 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 265 | 73 |
| Furosemide | Furosemide | 260 | 105 |
| Montelukast Sodium | Montelukast Sodium | 240 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 85 |
| Eliquis | Apixaban | 234 | 56 |
| Farxiga | Dapagliflozin Propanediol | 212 | 60 |
| Tramadol Hcl | Tramadol Hcl | 192 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 186 | 46 |
| Buspirone Hcl | Buspirone Hcl | 185 | 51 |
| Trazodone Hcl | Trazodone Hcl | 185 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 58 |
| Omeprazole | Omeprazole | 176 | 54 |
| Prednisone | Prednisone | 174 | 117 |
| Azithromycin | Azithromycin | 172 | 142 |
| Ozempic | Semaglutide | 167 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 55 |
| Lisinopril | Lisinopril | 158 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 155 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 60 |
| Carvedilol | Carvedilol | 154 | 48 |
| Amitriptyline Hcl | Amitriptyline Hcl | 151 | 46 |
| Alprazolam | Alprazolam | 148 | 28 |
| Ondansetron Odt | Ondansetron | 145 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 41 |
| Ibuprofen | Ibuprofen | 138 | 44 |
| Metformin Hcl | Metformin Hcl | 137 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 41 |
| Glipizide Er | Glipizide | 126 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 126 | 96 |
| Symbicort | Budesonide/Formoterol Fumarate | 120 | 37 |
| Celecoxib | Celecoxib | 116 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 39 |
| Bupropion Xl | Bupropion Hcl | 111 | 39 |
| Sucralfate | Sucralfate | 106 | 45 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 35 |
| Spiriva Respimat | Tiotropium Bromide | 101 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 22 |
| Memantine Hcl | Memantine Hcl | 93 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 41 |
| Pregabalin | Pregabalin | 85 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 70 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 18 |
| Meloxicam | Meloxicam | 80 | 25 |
| Spironolactone | Spironolactone | 78 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 18 |
| Allopurinol | Allopurinol | 70 | 22 |
| Mupirocin | Mupirocin | 70 | 55 |
| Sertraline Hcl | Sertraline Hcl | 70 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 13 |
| Aripiprazole | Aripiprazole | 66 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 15 |
| Vraylar | Cariprazine Hcl | 63 | 12 |
| Fluconazole | Fluconazole | 62 | 41 |
| Levofloxacin | Levofloxacin | 62 | 54 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 60 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 49 |
| Promethazine Hcl | Promethazine Hcl | 56 | 16 |
| Baclofen | Baclofen | 54 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 46 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 13 |
| Myrbetriq | Mirabegron | 53 | 14 |
| Linzess | Linaclotide | 51 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 18 |
| Simvastatin | Simvastatin | 51 | 14 |
| Temazepam | Temazepam | 51 | 14 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 17 |
| Metronidazole | Metronidazole | 48 | 39 |
| Topiramate | Topiramate | 47 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 46 | 36 |
| Clindamycin Hcl | Clindamycin Hcl | 46 | 41 |
| Clonazepam | Clonazepam | 45 | 19 |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 45 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 21 |
| Finasteride | Finasteride | 44 | 17 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 23 |
| Movantik | Naloxegol Oxalate | 44 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Clonidine | Clonidine | 42 | 11 |
| Methocarbamol | Methocarbamol | 41 | 14 |
| Midodrine Hcl | Midodrine Hcl | 41 | 14 |
| Mirtazapine | Mirtazapine | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | 30 |
| Estradiol | Estradiol | 38 | 18 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Ofloxacin | Ofloxacin | 33 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | 13 |
| Glipizide | Glipizide | 31 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 11 |
| Veozah | Fezolinetant | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 25 | 13 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Constulose | Lactulose | 22 | 16 |
| Diazepam | Diazepam | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 17 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Humira(Cf) Pen | Adalimumab | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Qulipta | Atogepant | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.04 · 40 records | Sumitomo Pharma America, Inc. | AREXVY, ARISTADA, BREZTRI, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, ENFLONSIA, GARDASIL 9, GEMTESA, JOURNAVX, LYBALVI, MAVYRET, NURTEC ODT, OTEZLA, Ozempic, PROCLAIM, REPATHA, ROTATEQ, Rybelsus, TRELEGY ELLIPTA, VAXNEUVANCE, VOQUEZNA, VRAYLAR, ZAVZPRET, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error